Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men

[1]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[2]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[3]  V. Fuster,et al.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[4]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[5]  C. Hennekens,et al.  An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.

[6]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[7]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[8]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[9]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[10]  W. Richardson,et al.  Selecting and Appraising Studies for a Systematic Review , 1997, Annals of Internal Medicine.

[11]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[12]  P. Ridker,et al.  Anti-Platelet Effects of 100 mg Alternate Day Oral Aspirin: A Randomized, Double-Blind, Placebo-Controlled Trial of Regular and Enteric Coated Formulations in Men and Women , 1996, Journal of cardiovascular risk.

[13]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[14]  G. Escolar,et al.  Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. , 1986, Thrombosis Research.

[15]  M. Harrison,et al.  A Sex Difference in the Effect of Aspirin on “Spontaneous” Platelet Aggregation in Whole Blood , 1983, Thrombosis and Haemostasis.

[16]  B. Weksler,et al.  Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.

[17]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[18]  M. Harrison,et al.  Sex difference in antithrombotic effect of aspirin. , 1989, Stroke.